Eohilia (budesonide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

		☐ URGEN	
MEMBER INFORMATION			
LAST NAME:		FIRST NAME:	
PHONE NUMBER:		DATE OF BIRTH:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
PATIENT INSURANCE ID I	NUMBER:		
MALE FEMALE	HEIGHT (IN/CM): W	/EIGHT (LB/KG): ALLERGIES:	
_		DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE	
OLLOWING LINK: PRIMETHERAPEUTICS.	•		
ATIENT'S ALITHODIZED D	EDDECENITATIVE (IE ADDITOAT	BLE):	
	EPRESENTATIVE (IF APPLICAT ATIVE'S PHONE NUMBER:		
NOTHIOMIZED REFRESERTA	THE STRICTE HOMBER.		
PRESCRIBER INFORMATION	ON		
LAST NAME:		FIRST NAME:	
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:	
NPI NUMBER:		DEA NUMBER:	
PHONE NUMBER:		FAX NUMBER:	
STREET ADDRESS:			
CITY:		STATE: ZIP CODE:	
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:	
MEDICATION OR MEDICA	AL DISPENSING INFORMATIO	N	
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF QUANTITY:	
•		THERAPY/REFILLS:	
NEW THERAPY	RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):		

Continued on next page.



Eohilia (budesonide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO	
MEDICATION/THERAPY (SPECIFY	DURATION OF THERAPY (SPECIFY	RESPONSE/REASON FOR	
DRUG NAME AND DOSAGE):	DATES):	FAILURE/ALLERGY:	
2. LIST DIAGNOSES:		ICD-10:	
☐ Eosinophilic Esophagitis (EoE)			
☐ Other Diagnosis ☐ ICD-10 C			
PRIOR AUTHORIZATION.	: PLEASE PROVIDE ALL RELEVANT CLINIC	CALINFORMATION TO SUPPORT A	
Clinical information:			
Will patient use in conjunction with a	clinical trial? □ Yes □ No		
<u> </u>	sinophilic esophagitis (EoE), defined as	15 eosinophils per high-power field on	
esophageal biopsy? ☐ Yes ☐ No			
Does the nationt have a history of clin	nical symptoms of esophageal dysfuncti	on (for example, eating problems	
1	a, vomiting, food impaction, weight loss		
and a substitution of the	.,	,,. = 1 	
Has the patient tried and had an inade	equate response to ONE standard corti	costeroid therapy (i.e., swallowed	
budesonide nebulizer suspension, swa	allowed fluticasone MDI) used in the tro	eatment of EoE? Yes No	
I	ce, hypersensitivity or contraindication		
used in the treatment of EOE that is no	ot expected to occur with the requested	d agent? 🗆 Yes 🗆 NO	
Has the patient tried and had an inad	equate response to ONE proton pump i	nhibitor (PPI) used in the treatment of	
EoE (documentation required)? ☐ Yes			
, , ,			
Is Eohilia being prescribed by, or in co	nsultation with a gastroenterologist, al	lergist, or immunologist? ☐ Yes ☐ No	
Has the patient previously been treat	ed with Eohilia? 🗆 Yes 🗆 No		
If yes, please provide date(s) of treatr	ment:		
in yes, pieuse provide date(s) or treat			
Are there any other comments, diagn	oses, symptoms, medications tried or fa	ailed, and/or any other information the	
physician feels is important to this rev	view?		
	e covered on all plans. This request may	be denied unless all required	
information is received.			



Eohilia (budesonide) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date:

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP - 4201 P.O. Box 64811 St. Paul, MN 55164-0811

